BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has entered into an agreement for the global co-development and ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.